Table 4.

Outcome measures used in a high-transmission area

Study	Primary Outcome	Secondary outcomes
Observational study: Dose-escalating clinical trial	% of patients with Adequate Clinical Response at d14 in each dosage group (= dose response)	% of patients with Adequate Clinical Response at d28
		% of patients with total parasite clearance at days 14 and 28
		% of patients experiencing adverse effects
Experimental study: Pragmatic Randomized Controlled Trial	‘clinical recovery’ at day 28 without need for re-treatment with the second-line anti-malarial	Axillary temperature <37.5’C at day 14
		Age-specific incidence of severe malaria days 0-28 (patients aged <5 years)
		incidence of new clinical episodes of malaria d15-28
		Mean haematocrit at day 28
		% of patients experiencing adverse events